CWP
VIR icon

Concord Wealth Partners’s Vir Biotechnology VIR Stock Holding History

Concord Wealth Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$5.06K – 1234
2022
Q4 		$5.06K Buy
+200
New +$4.9K ﹤0.01% 762
2022
Q3 		– Sell
-232
Closed -$6K – 1110
2022
Q2 		$6K Hold
232
– – ﹤0.01% 798
2022
Q1 		$6K Hold
232
– – ﹤0.01% 883
2021
Q4 		$10K Buy
+232
New +$9.09K ﹤0.01% 791

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Concord Wealth Partners's VIR Position: Q1 2023 in Review

Concord Wealth Partners sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 200 shares — an estimated $5.06K sold.

Concord Wealth Partners first reported a position in VIR in Q4 2021 and held it in 4 quarters. The position peaked at $10K in Q4 2021. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Concord Wealth Partners reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 200 Vir Biotechnology shares in Q1 2023, an estimated $5.06K.
  • Concord Wealth Partners first reported a position in Vir Biotechnology in Q4 2021 and held it in 4 quarters.
  • Concord Wealth Partners's Vir Biotechnology position peaked at $10K in Q4 2021.
  • 232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.